Literature DB >> 22106818

Distinct effects of acute pretreatment with lipophilic and hydrophilic statins on myocardial stunning, arrhythmias and lethal injury in the rat heart subjected to ischemia/reperfusion.

S Čarnická1, A Adameová, M Nemčeková, J Matejíková, D Pancza, T Ravingerová.   

Abstract

Although both lipophilic and more hydrophilic statins share the same pathway of the inhibition of HMG-CoA reductase, their pleiotropic cardioprotective effects associated with the ability to cross cellular membranes, including membranes of heart cells, may differ. To test this hypothesis, isolated rat hearts were Langendorff-perfused either with simvastatin (S, 10 micromol/l) or pravastatin (P, 30 micromol/l), 15 min prior to ischemia. Control untreated hearts (C) were perfused with perfusion medium only. Postischemic contractile dysfunction, reperfusion-induced ventricular arrhythmias and infarct size were investigated after exposure of the hearts to 30-min global ischemia and 2-h reperfusion. Both lipophilic S and hydrophilic P reduced the severity of ventricular arrhythmias (arrhythmia score) from 4.3 +/- 0.2 in C to 3.0 +/- 0 and 2.7 +/- 0.2 in S and P, respectively, (both P < 0.05), decreased the duration of ventricular tachycardia and suppressed ventricular fibrillation. Likewise, the extent of lethal injury (infarct size) determined by tetrazolium staining and expressed in percentage of risk area, was significantly lower in both treated groups, moreover, the effect of P was more pronounced (27 +/- 2 % and 10 +/- 2 % in S and P groups, respectively, vs. 42 +/- 1 % in C; P < 0.05). In contrast, only S, but not P, was able to improve postischemic recovery of left ventricular developed pressure (LVDP; 48 +/- 12 % of preischemic values vs. 25 +/- 4 % in C and 21 +/ -7 % in P groups; P < 0.05). Our results suggest that differences in water solubility of statins indicating a different ability to cross cardiac membranes may underlie their distinct cardioprotective effects on myocardial stunning and lethal injury induced by ischemia/reperfusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22106818     DOI: 10.33549/physiolres.932232

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  7 in total

1.  Effects of rosuvastatin and atorvastatin on nonsustained ventricular tachycardia in patients with ST-elevation myocardial infarction: a retrospective analysis.

Authors:  Xianqing Hu; Jian Cheng; Chunjian Li
Journal:  Eur J Clin Pharmacol       Date:  2017-09-30       Impact factor: 2.953

2.  Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II.

Authors:  Haiming Dang; Bangrong Song; Ran Dong; Hongjia Zhang
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

3.  Pretreatment of Adipose Derived Stem Cells with Curcumin Facilitates Myocardial Recovery via Antiapoptosis and Angiogenesis.

Authors:  Jianfeng Liu; Ping Zhu; Peng Song; Weiping Xiong; Haixu Chen; Wenhui Peng; Shuxia Wang; Shan Li; Zhiqing Fu; Yutang Wang; Haibin Wang
Journal:  Stem Cells Int       Date:  2015-05-05       Impact factor: 5.443

4.  Simvastatin activates single skeletal RyR1 channels but exerts more complex regulation of the cardiac RyR2 isoform.

Authors:  Elisa Venturi; Chris Lindsay; Sabine Lotteau; Zhaokang Yang; Emma Steer; Katja Witschas; Abigail D Wilson; James R Wickens; Angela J Russell; Derek Steele; Sarah Calaghan; Rebecca Sitsapesan
Journal:  Br J Pharmacol       Date:  2018-02-05       Impact factor: 8.739

5.  Cardioprotective effects of Prolame and SNAP are related with nitric oxide production and with diminution of caspases and calpain-1 activities in reperfused rat hearts.

Authors:  Nadia Giovanna Román-Anguiano; Francisco Correa; Agustina Cano-Martínez; Aurora de la Peña-Díaz; Cecilia Zazueta
Journal:  PeerJ       Date:  2019-07-29       Impact factor: 2.984

6.  Atorvastatin protects the proliferative ability of human umbilical vein endothelial cells inhibited by angiotensin II by changing mitochondrial energy metabolism.

Authors:  Ye Chang; Yuan Li; Ning Ye; Xiaofan Guo; Zhao Li; Guozhe Sun; Yingxian Sun
Journal:  Int J Mol Med       Date:  2017-10-19       Impact factor: 4.101

7.  Pravastatin But Not Simvastatin Improves Survival and Neurofunctional Outcome After Cardiac Arrest and Cardiopulmonary Resuscitation.

Authors:  Stefan Bergt; Andrea Grub; Steffen Wagner; Hauke Engelke; Gabriele Nöldge-Schomburg; Brigitte Vollmar; Jan P Roesner; Nana-Maria Wagner
Journal:  JACC Basic Transl Sci       Date:  2017-04-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.